Pirtobrutinib shows promise as a first-line CLL/SLL treatment with better safety and high response rates vs. ibrutinib.

In a phase 3 trial presented at the 2025 ASH meeting, pirtobrutinib showed non-inferior overall response rates compared to ibrutinib in untreated and relapsed/refractory CLL/SLL patients, with higher response rates in treatment-naive individuals and a more favorable safety profile, including lower rates of atrial fibrillation and hypertension, suggesting potential for broader use as a first-line therapy.